A lymphoma diagnosis arrives quickly — often through a biopsy result after noticing an enlarged lymph node that didn't go away. The urgency varies by subtype: DLBCL and Burkitt lymphoma require treatment to start within days to weeks; follicular lymphoma may allow more time. Either way, you need to understand your medical aid situation immediately. This guide walks you through the steps.
Your Immediate Protection
Lymphoma — both Hodgkin and Non-Hodgkin — is a PMB condition. Your scheme must fund your diagnosis, staging, and treatment regardless of your plan option or any waiting periods. The legal obligation is clear. What varies is how much your scheme will pay, and whether specific medicines (particularly rituximab and second-line regimens) are funded as PMB or require exceptional-needs authorisation.
Step 1: Call Oncology Case Management Now
Do not wait until after your first treatment appointment. Call your scheme and ask specifically for oncology case management — the clinical team that handles cancer patients, not the general member services line.
Tell them: 1. You have been diagnosed with lymphoma (Hodgkin or Non-Hodgkin — specify which if known). 2. You need to register your PMB oncology benefit. 3. You need a case manager assigned before treatment starts.
For aggressive lymphomas (DLBCL, Burkitt), your oncologist may need to start chemotherapy within days. Your case manager needs to issue pre-authorisation immediately. Escalate to urgent if your haematologist indicates treatment is time-sensitive — schemes have urgent clinical review processes.
Step 2: Confirm Rituximab Funding (B-Cell NHL Patients)
If you have been diagnosed with a B-cell NHL (the most common type — includes DLBCL, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma), your treatment will almost certainly include rituximab. Confirm with your case manager:
"Is rituximab funded as part of the PMB minimum treatment for [your specific subtype]?"
Most SA schemes fund rituximab as part of R-CHOP for DLBCL — but this should be confirmed in writing before your first cycle, not discovered as a problem on your first claim.
If your scheme classifies CHOP (without rituximab) as the PMB minimum and asks your oncologist to motivate for rituximab as exceptional-needs: have your haematologist submit the motivation immediately. Standard of care evidence for rituximab in B-cell NHL is overwhelming and most motivations are approved.
Step 3: Find Your Oncology Sub-Limit
Ask your case manager for your plan's annual oncology sub-limit. What this means for you:
Hodgkin Lymphoma patients: ABVD chemotherapy for first-line HL costs R100,000–R280,000 depending on the number of cycles. Most plans with sub-limits above R250,000 are adequate for first-line treatment. The concern arises if treatment fails and second-line or pembrolizumab is needed.
DLBCL (and other aggressive NHL) patients: R-CHOP × 6 cycles costs R180,000–R350,000. Most mid-tier plans (R250,000–R400,000 sub-limits) are adequate for uncomplicated first-line treatment. If relapse occurs and ASCT (autologous stem cell transplant) is needed, costs jump to R350,000–R600,000+ and sub-limit adequacy becomes critical.
Step 4: Understand the PET/CT Staging Process
PET/CT is the gold standard for lymphoma staging and for assessing treatment response mid-way through chemotherapy (interim PET). It is superior to CT alone. Most schemes fund PET/CT as part of the PMB staging workup — but not all do without a fight.
Have your haematologist write the referral as "PET/CT for lymphoma staging — required for PMB treatment planning" — clearly linking it to the PMB oncology benefit. If your scheme attempts to decline on cost grounds, escalate to the case manager with your haematologist's clinical justification.
Step 5: Consider Stem Cell Transplant Access (High-Risk or Relapsed Patients)
For high-risk DLBCL or relapsed/refractory aggressive NHL, autologous stem cell transplant (ASCT) may be part of the treatment plan. ASCT is a PMB benefit for qualifying patients — but it is only available at certain tertiary oncology centres with transplant capability.
Confirm with your case manager: - Which facilities in your scheme's DSP network perform ASCT? - Is your treating haematologist affiliated with one of these centres?
If your treating oncologist is at a centre that is NOT in your DSP network for transplant, this needs to be sorted before ASCT is needed — not after relapse is confirmed.
Step 6: Should You Switch Plans?
For Hodgkin Lymphoma (young adults, first-line treatment): Most plans with a R250,000+ sub-limit are adequate. Switching is usually not necessary for uncomplicated first-line HL.
For aggressive NHL or relapsed disease: If your current plan's sub-limit is below R400,000, consider moving to a higher option within your scheme before the new benefit year. Intra-scheme option changes do not trigger new waiting periods for an existing diagnosis.
Do not switch to an entirely new scheme while in treatment. Pre-existing condition provisions and new-joiner waiting periods apply.
Emergency Resources
CANSA (Cancer Association of SA): 0800 22 6622 (toll-free, weekdays) Lymphoma Foundation SA: lymphomafoundation.co.za (for support and navigation) Council for Medical Schemes: 0861 123 267 | www.medicalschemes.co.za
What AURA Does Differently
AURA analyses rituximab funding patterns, oncology sub-limits, and transplant-facility access across 112 plans — the factors that actually determine your financial exposure during lymphoma treatment.
Get help understanding your cover options →